NAV

Famprofazone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Famprofazone
DrugBank Accession Number
DB16702
Background

Famprofazone is a nonsteroidal anti-inflammatory agent found in combination products such as ‘Gewodin’ which is marketed in Taiwan.2 It is important to note that the drug is metabolized to methamphetamine and amphetamine in the body and can lead to positive tests results for illicit drug use.1,2 Famprofazone is included in the list of prohibited substances specified by the ‘World Anti-Doping Agency’ (WADA).3

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 377.532
Monoisotopic: 377.24671263
Chemical Formula
C24H31N3O
Synonyms
  • Famprofazone
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
HN0NCX453C
CAS number
22881-35-2
InChI Key
GNUXVOXXWGNPIV-UHFFFAOYSA-N
InChI
InChI=1S/C24H31N3O/c1-18(2)23-22(17-25(4)19(3)16-20-12-8-6-9-13-20)26(5)27(24(23)28)21-14-10-7-11-15-21/h6-15,18-19H,16-17H2,1-5H3
IUPAC Name
1-methyl-5-{[methyl(1-phenylpropan-2-yl)amino]methyl}-2-phenyl-4-(propan-2-yl)-2,3-dihydro-1H-pyrazol-3-one
SMILES
CC(C)C1=C(CN(C)C(C)CC2=CC=CC=C2)N(C)N(C1=O)C1=CC=CC=C1

References

General References
  1. Chan KH, Hsu MC, Tseng CY, Chu WL: Famprofazone use can be misinterpreted as methamphetamine abuse. J Anal Toxicol. 2010 Jul-Aug;34(6):347-53. doi: 10.1093/jat/34.6.347. [Article]
  2. National Center for Advancing Translational Sciences - Famprofazone [Link]
  3. World Anti-Doping Agency: Prohibited In-Competition [Link]
Human Metabolome Database
HMDB0041891
ChemSpider
3209
ChEBI
93799
ChEMBL
CHEMBL1475693
Wikipedia
Famprofazone

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0602 mg/mLALOGPS
logP3.52ALOGPS
logP4.44Chemaxon
logS-3.8ALOGPS
pKa (Strongest Basic)9.1Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area26.79 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity116.98 m3·mol-1Chemaxon
Polarizability43.79 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-0029000000-c5ac109a2ed37aca1a85
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-0019000000-daa37602e4722ca4012a
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-004l-2191000000-74a26e4fe7f60489e250
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0290000000-c1f18096dd06b621af2a
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-0931000000-6ba06fbd14f9c67674d4
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00g0-1951000000-bb7d5359a147969cb4d7
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-200.6985731
predicted
DarkChem Lite v0.1.0
[M-H]-196.35971
predicted
DeepCCS 1.0 (2019)
[M+H]+200.7622731
predicted
DarkChem Lite v0.1.0
[M+H]+198.7177
predicted
DeepCCS 1.0 (2019)
[M+Na]+200.8448731
predicted
DarkChem Lite v0.1.0
[M+Na]+205.76028
predicted
DeepCCS 1.0 (2019)

Drug created at July 07, 2021 15:27 / Updated at July 12, 2021 03:34